Published online before print July 25, 2008, doi: 10.1161/CIRCRESAHA.108.181487
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Molecular Medicine |
Increased FOG-2 in Failing Myocardium Disrupts Thyroid Hormone–Dependent SERCA2 Gene Transcription
From the MCRI Center for Translational Genomics (R.R., S.G., E.C.W., J.W., J.B., R.D.P., G.S.H.), Molecular Cardiology Research Institute, Tufts Medical Center, Boston, Mass; Cardiology Unit (M.P.), Massachusetts General Hospital, Boston, Mass; Department of Medicine (E.C.S.), University of Chicago, Ill; and Division of Endocrinology and Metabolism (W.H.D.), University of California, San Diego.
Correspondence to Gordon S. Huggins, MD, MCRI Center for Translational Genomics, Molecular Cardiology Research Institute, Tufts University School of Medicine, 750 Washington St, Box 8486, Boston, MA 02111. ghuggins{at}tuftsmedicalcenter.org
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Reduced expression of sarcoplasmic reticulum calcium ATPase (SERCA)2 and other genes in the adult cardiac gene program has raised consideration of an impaired responsiveness to thyroid hormone (T3) that develops in the advanced failing heart. Here, we show that human and murine cardiomyopathy hearts have increased expression of friend of GATA (FOG)-2, a cardiac nuclear hormone receptor corepressor protein. Cardiac-specific overexpression of FOG-2 in transgenic mice led to depressed cardiac function, activation of the fetal gene program, congestive heart failure, and early death. SERCA2 transcript and protein levels were reduced in FOG-2 transgenic hearts, and FOG-2 overexpression impaired T3-mediated SERCA2 expression in cultured cardiomyocytes. FOG-2 physically interacts with thyroid hormone receptor-
1 and abrogated even high levels of T3-mediated SERCA2 promoter activity. These results demonstrate that SERCA2 is an important target of FOG-2 and that increased FOG-2 expression may contribute to a decline in cardiac function in end-stage heart failure by impaired T3 signaling.
Key Words: friend of GATA-2 • thyroid hormone receptor • sarcoplasmic reticulum calcium-activated ATPase-2 • heart failure
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Congestive heart failure (CHF) is a lethal condition and represents the final common end point of many forms of heart disease. A hallmark feature of failing hearts is a downregulation of sarcoplasmic reticulum calcium ATPase (SERCA)2 and
-myosin heavy chain (MHC), which are critical components of the myocyte excitation–contraction coupling machinery.1,2 Although the regulatory mechanisms that affect these changes are poorly understood, a similar pattern of gene expression seen in the hypothyroid heart suggests that impaired thyroid hormone (T3) responsiveness may contribute to this transcriptional switch.3 Indeed, T3 is required for the physiological increase of SERCA2 and MHC after birth.4 Low SERCA2 and MHC expression levels in the hypothyroid or failing heart are recovered following T3 replacement.5,6 In heart failure models, decreased circulating T3 levels,7 accelerated myocardial T3 turnover,8 and altered thyroid hormone receptor (TR) isoform expression9 have been implicated mechanisms of cardiac-restricted T3 resistance.
T3 regulates transcription through interaction with the ligand-binding domain of high-affinity nuclear TR proteins that recognize T3 response elements (TREs) on target genes.10 Three major TR isoforms, TR1, TR2, and TRβ1, are expressed in the heart. TR1 and TR2 are abundantly expressed in the ventricular compact zone, which contributes the greatest force output from the heart, whereas TRβ1 expression is limited to the peripheral ventricular conduction system.11 TR1, but not TRβ1, is required for normal SERCA2 and MHC expression in vivo, and mouse TR gene deletion models support a predominant role for TR1 in the regulation of cardiac contractile and electrophysiological functions.12 Without T3, TR proteins bind TREs and decrease basal gene expression through the recruitment of corepressor complexes. On T3 binding to TR, these complexes are displaced and coactivator proteins are recruited that modulate chromatin structure and enhance gene expression.13 Because an imbalance favoring TR corepressor binding impairs T3 responsiveness,14–16 we considered whether a cardiac-enriched corepressor protein may mediate local cardiac T3 resistance in CHF.
FOG-2 (friend of GATA-2) is a multi–zinc finger nuclear corepressor protein necessary for normal development of the heart and, in particular, the left ventricular (LV) compact zone.17,18 FOG-2 was originally identified as a GATA4-interacting protein19,20 but also interacts with nuclear hormone receptors, chicken ovalbumin upstream protein transcription factor (COUP-TF)221 and retinoid-X receptor- (RXR).22 In models of load-induced heart failure, GATA4, COUP-TF2, and RXR regulate components of the cardiac gene program that affect natriuretic peptide expression,21,22 cardiac metabolism,23 and myocyte architecture.24 Although FOG-2 represses the transcriptional activities of GATA4,19 COUP-TF2,21 and ligand-bound RXR22 in cultured cardiomyocytes, the role of FOG-2 in the adult heart remains undefined.
Here, we report that FOG-2 levels are increased in human end-stage heart failure and in a mouse model of dilated cardiomyopathy. Transgenic (Tg) mice with targeted overexpression of FOG-2 in the heart have reduced systolic and diastolic function. Diminished expression of SERCA2 is a primary finding associated with the cardiomyopathy created by FOG-2 overexpression. We demonstrate that FOG-2 binds TR1 and impairs T3-mediated transcription of the SERCA2 promoter. Taken together, we identify a novel mechanism of cardiac resistance to T3 signaling caused by increased FOG-2 expression that may contribute directly to heart failure progression.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mice
MHC-CREB-S133A Tg mice25 and Fog-2+/– (heterozygous null) mice17 were described previously. MHC-FOG-2 Tg mice were produced following injection of a transgene including the full-length mouse FOG-2 cDNA (base pairs 132 to 4770) downstream of the murine MHC promoter26 into newly fertilized ICR (Taconic) mouse embryos. Founders identified by Southern blot analysis with FOG-2 probe (nucleotides 132 to 1207) were bred with ICR mice. Histological analysis was performed on hearts fixed in 4% paraformaldehyde and processed into paraffin blocks. Cardiac functional analysis was performed by echocardiography and cardiac catheterization (expanded Materials and Methods section, available in the online data supplement at http://circres.ahajournals.org). Protein and total RNA extracts for gene expression analysis were prepared using standard methods (online data supplement, expanded Materials and Methods section). Studies were approved by the Institutional Review Board for Animal Care and Use Committee at Tufts Medical Center and Harvard University.
Gene Expression Analysis
Northern blotting of total RNA was performed with [32P]-labeled FOG-2 cDNA template (nucleotides 132 to 1207) and 18S probes (online data supplement, expanded Materials and Methods section). Quantitative real-time RT-PCR (qRT-PCR) was performed using cDNA synthesized from total RNA and amplified in triplicate with custom primer sequences (online data supplement, expanded Materials and Methods section). Western immunoblotting was performed with SERCA2 (Affinity BioReagents), calsequestrin (Upstate), GAPDH (Research Diagnostics), and FOG-2 (Santa Cruz Biotechnology) antibodies or FOG-2 antiserum,26 followed by a species appropriate HRP-conjugated secondary antibody. Membranes incubated with ECL Plus (Amersham) were imaged on a Typhoon 9410 System (Amersham), and band densities were quantified using ImageQuant software (Amersham).
Adenovirus Infection
Full-length mouse FOG-2 cDNA (nucleotides 132 to 4770) was subcloned to generate a recombinant adenovirus expressing both FOG-2 and enhanced green fluorescent protein (EGFP) (Ad-FOG-2) using the AdEasy Adenoviral Vector System (Stratagene).27 A control vector expressing β-galactosidase and EGFP (Ad-LacZ) was provided by the Adenoviral Core Facility (Tufts Medical Center). Primary cultures of neonatal rat ventricular myocytes prepared as previously described28 were grown to 70% to 80% confluence. Media was exchanged with DMEM containing 2% charcoal-stripped fetal bovine serum. Neonatal rat ventricular myocyte cultures were infected with Ad-LacZ or Ad-FOG-2 for 12 hours and grown in media supplemented with vehicle (100 nmol/L NaOH) or T3 (Sigma). Infection at an approximate multiplicity of infection (moi) of 8 resulted in a >95% cellular EGFP expression at 72 hours (Nikon Eclipse E800). Cells were harvested for RNA at 48 hours and for protein at 72 hours using standard methods (online data supplement, expanded Materials and Methods section).
Interaction Assays
All plasmid constructs are detailed in the online data supplement (expanded Materials and Methods section). HEK-293 cells were transfected with equal parts pcDNA3-FOG-219 with either pCR3-rTR1 or pCR3-myc-rTR1 using Polyfect (Qiagen). Cellular extract was diluted in an immunoprecipitation buffer and precipitated with FOG-2 antiserum,26 myc epitope antibody (Tufts University Core Facility), or no antibody (online data supplement, expanded Materials and Methods section) and immunoblotted with FOG-2 antiserum.26 Glutathione S-transferase (GST) pull-down assays were performed with fusion proteins containing either zinc fingers 5 and 6 (amino acids 497 to 831) or zinc fingers 7 and 8 (amino acids 752 to 1151)21 and recombinant rat TR1 and TR2 proteins labeled with [35S]-methionine (Amersham) using the TnT T7 Coupled Reticulocyte System (Promega) (online data supplement, expanded Materials and Methods section).
Transient Transfection Assays
The p0.6kb-SERCA2-tk-luciferase, containing the proximal rat SERCA2 promoter fused to the thymidine kinase (tk) promoter, has been described previously.29 All other plasmid constructs are described in the online data supplement (expanded Materials and Methods section). Embryonic chick ventricular myocytes were prepared as previously described30 and grown to 90% to 95% confluence. Medium was replaced with DMEM containing 2% charcoal-stripped horse serum. Triplicate wells were each transfected with 150 ng of luciferase reporter plasmid, 400 ng of each expression vector (pcDNA3.1-hTR1, pcDNA-mFOG-2 or pCR3 to normalize amounts of transfected plasmid) and 10 ng of CMV–β-galactosidase control vector using Lipofectamine 2000 (Invitrogen). After 18 hour, the media was replaced with DMEM/2% charcoal-stripped horse serum supplemented with vehicle or T3. After 24 hours the cells were lysed and luciferase (Promega) and β-galactosidase (Applied Biosystems) activity were measured using a luminometer (Thermo Labsystems). Fold activation is expressed as a ratio of luciferase activity to β- galactosidase activity and normalized across experiments to either the empty vector or FOG-2 reference condition.
Statistical Analysis
Microarray expression differences were determined by significance analysis of microarrays.31 Statistically significant differences between Tg and nontransgenic (NTg) groups were determined by an unpaired t test or log-rank survival analysis when appropriate. All other statistical analyses were performed by 2-way ANOVA, followed by a Bonferroni post test using GraphPad Prism version 4.0 software. Data are expressed as means±SEM. A minimum value of P<0.05 was accepted as statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
FOG-2 Protein Is Increased in Failing Hearts
To explore FOG-2 expression in the setting of heart failure, we analyzed microarray data (Gene Expression Omnibus GDS1362) from 37 human cardiac tissue samples taken from nonfailing (NF) (n=6), nonischemic cardiomyopathy (n=21), and ischemic dilated cardiomyopathy (n=10).32 Significance analysis of microarrays identified FOG-2 as a differentially expressed gene among cardiomyopathy samples with a local false discovery rate of 0.06%. FOG-2 expression was increased 1.8-fold in nonischemic cardiomyopathy and 1.6 fold in ischemic dilated cardiomyopathy samples, respectively compared with nonfailing control (Figure 1a).
|
To observe whether increased FOG-2 expression is associated with heart failure independent of concomitant therapy, we studied CREB-S133A mice, a well-characterized model of human dilated cardiomyopathy. These mice develop progressive chamber dilatation and contractile dysfunction by 8 weeks of age and begin to die from heart failure by 10 weeks of age.25 Whereas 6-week-old CREB-S133A mice did not have significant differences in FOG-2 expression compared with NTg littermate controls (1.51±0.39-fold difference, P=0.19), a 2.53±0.45-fold increase in FOG-2 protein (P<0.05) was observed at 12 weeks of age (Figure 1b). Furthermore, increased myocardial FOG-2 protein expression was also observed in mice subjected to 14 days of transverse aortic constriction, at which time point, LV fractional shortening was significantly depressed (Figure I in the online data supplement). Thus, increased FOG-2 expression is associated with decompensated heart function.
FOG-2 Tg Mice Develop Heart Failure
To determine the consequence of increased FOG-2 expression in the adult heart, we generated 5 lines of cardiac-specific Tg mice with FOG-2 expression driven by the MHC promoter.33 One line did not express FOG-2. The remaining 4 lines were found to have low (line 2467, FOG-2-low), medium (line 1711, FOG-2-med), and high (lines 2926 and 4102, FOG-2-high) levels of FOG-2 expression. Northern and Western blot analysis confirmed FOG-2 transgene expression in the heart (Figure 2a and 2b).
|
) (n=75), FOG-2-high Tg (
) (n=46), and NTg littermate control (
) (n=44) mice. Differences in survival rates between the Tg and NTg groups were significant by the log rank test (P<0.05). d, Representative coronal sections of hearts from NTg littermate control and FOG-2-med Tg mice showed no gross hypertrophy of the ventricles. Scale bar, 100 µm. e, Hemodynamic analysis of FOG-2-med Tg and NTg littermate control mice. The means±SEM maximum (top) and minimum (bottom) first derivative of LV pressure tracings (dP/dt) measured at baseline and at indicated time points following stimulation with isoproterenol. Reductions in both maximum and minimum dP/dt in the Tg (
Genotypic analysis performed at 3 weeks of age revealed equivalent numbers of Tg and NTg pups in all lines, suggesting that FOG-2 overexpression from the MHC promoter did not influence viability during embryonic development. The FOG-2-med and -high lines demonstrated significant morbidity and mortality beginning as early as 6 weeks of age (Figure 2c) and were observed to have lethargy, tachypnea, and peripheral edema, consistent with overt heart failure.
Hearts from FOG-2 mice displayed grossly normal-sized ventricles (Figure 2d) and enlarged atria with mural thrombi (supplemental Figure IIA). Cardiac valve leaflet structure was unremarkable (supplemental Figure IIB). A trend toward greater whole heart mass relative to body weight in Tg versus NTg hearts (4.21±0.08 versus 3.97±0.09 mg/g, P=0.06) was attributable to enlarged atria. The ventricular to body weight (3.5±0.1 versus 3.6±0.1 mg/g, P=NS) and tibia length (5.9±0.2 versus 6.0±0.2 gm/mm, P=NS) ratios were similar, as were cardiomyocyte cross-sectional areas (data not shown). Pico Sirius staining showed increased interstitial fibrosis (supplemental Figure III), consistent with findings in cardiomyopathy25 and hypothyroidism.34
To evaluate the functional cardiac phenotype underlying the susceptibility to heart failure in FOG-2 mice, we assessed contractile performance in 8- to 10-week-old FOG-2-med Tg and NTg mice. FOG-2 mice had mildly dilated LV systolic dimensions by echocardiography with significantly reduced fractional shortening (Table). Invasive pressure measurement showed reduced LV systolic pressure in FOG-2 mice (61.8±6.1 versus 82.4±6.7 mm Hg, P<0.05), whereas LV diastolic pressures were similar. At baseline, FOG-2 mice revealed a trend toward depressed systolic function (dP/dtmax 2750±288 versus 3866±615 mm Hg/sec, P=0.09) and diastolic relaxation (dP/dtmin, –2242±258 versus –3471±578 mm Hg/sec, P=0.05) that became significant following isoproterenol challenge (Figure 2d).
|
SERCA2 Is a Downstream Target of FOG-2
Because FOG-2 mice demonstrated findings consistent with cardiomyopathy, gene expression was evaluated in 4- to 6-week-old FOG-2-high mice. FOG-2 mouse ventricles had increased B-type natriuretic peptide, β-myosin heavy chain (βMHC), and atrial natriuretic factor (supplemental Figure III), almost significantly decreased MHC expression (P=0.06), and significantly decreased SERCA2 mRNA levels (Figure 3a) and protein levels (Figure 3b), which were similarly observed in FOG-2-med mice (mRNA, P<0.01). To address potential concerns of overexpression artifact, we also measured SERCA2 protein levels in Fog-2+/– (heterozygous null) mice. In this setting of reduced FOG-2 gene dosage, SERCA2 protein levels were increased nearly 2-fold (Figure 3c).
|
To examine the effects of FOG-2 on endogenous SERCA2 expression independently from the potential secondary effects of heart failure, we infected cultured neonatal rat ventricular cardiomyocytes with a recombinant adenovirus expressing FOG-2. Ad-FOG-2 infection resulted in a dose-dependent increase in FOG-2 protein and a significant dose-dependent decrease in SERCA2 protein with maximal suppression of SERCA2 to levels that were half of that quantified in uninfected cells (Figure 4a and 4b). T3 treatment increased SERCA2 expression; however, FOG-2 overexpression repressed this effect at the protein (Figure 4a and 4b) and transcript (Figure 4d) levels. Importantly, FOG-2 did not alter expression of calsequestrin, another calcium-handling protein specific to cardiomyocytes (Figure 4c). These results are consistent with SERCA2 being a downstream target of FOG-2 and show that FOG-2 abrogates T3-mediated transcription of the endogenous SERCA2 gene.
|
P<0.05 vs moi 0/+T3 control. All data from at least three independent experiments.
FOG-2 Physically Interacts With TR1
Because FOG-2 can bind nuclear hormone receptors,21,22 we explored the interaction of FOG-2 with TR1, the predominant regulator of SERCA2 expression in vivo.11 In HEK-293 cells, FOG-2 was overexpressed with either TR1 or myc-tagged TR1. A FOG-2 antiserum recovered similar amounts of FOG-2 from both extracts (Figure 5a, right). By comparison, the myc antibody recovered FOG-2 only when coexpressed with the myc-tagged TR1 (Figure 6a, middle), thus identifying a specific association between FOG-2 and myc-TR1. Furthermore, in vitro–translated TR1 was retained by GST-FOG-2-Zn7–8, but not by FOG-2-Zn5–6 or GST alone, in the presence or absence of T3 (Figure 5b). We also compared the retention of TR1 with TR2, an alternative product of the Thra gene that has a distinct C terminus (CT).35 GST-FOG-2-Zn7–8 selectively retained the TR1-CT in the presence or absence of T3, but not the TR2-CT (Figure 5b).
|
|
A functional analysis of the interaction of FOG-2 with TR1 was performed in transient transfection studies of cultured cardiomyocytes using a reporter plasmid regulated by 2 tandem repeats of the consensus TRE sequence (Figure 5c). Transfection of TR1 alone significantly repressed basal activity of the consensus TREx2-tk reporter by >50%, whereas T3 treatment increased activity by 
8-fold. Although FOG-2 did not further repress activity beyond the level produced by TR1 in the absence of T3, FOG-2 significantly abrogated transactivation by TR1 following T3 treatment. Immunoblot analysis of cotransfected COS-7 cell lysates showed preserved, if not greater, TR1 protein expression when coexpressed with FOG-2, suggesting that the diminished reporter activity was not caused by lower TR1 protein levels (data not shown). Furthermore, whereas the FOG-2-R3A mutant,36 which lacks repressive activity, permitted continued repression of basal reporter activity by TR1 in the absence of T3, the FOG-2-R3A mutant did not abrogateT3-mediated TR1 transactivation (Figure 5c). Taken together, these results show a ligand-independent interaction between the CT of FOG-2 including zinc-fingers 7 to 8 (amino acids 752 to 1151) and the CT of TR1 and suggest that FOG-2 abrogation of T3-dependent TR1 transactivation requires the FOG-2 N-terminal repressive domain.
FOG-2 Abrogates T3-Mediated SERCA2 Promoter Activity
Further transient transfection studies of cultured cardiomyocytes were performed using a T3-responsive fragment of the SERCA2 promoter that includes multiple TREs.37 To isolate the effect of FOG-2 on T3-mediated activation, we analyzed relative luciferase activity of the SERCA2-tk reporter29 with respect to the basal effects of FOG-2 in the absence of T3. Similar to its effects on the consensus TREx2-tk reporter, FOG-2 did not further repress activity beyond the level produced by TR1 in the absence of T3 and significantly abrogated T3-mediated transactivation to basal levels (Figure 6a).
Similar abrogation of T3-mediated activity was observed using heterologous tk promoters consisting of 3 tandem repeats of 2 SERCA2 TREs (TRE1 and TRE2) that preferentially bind TR1 (Figure 6b).37 Furthermore, although increasing doses of T3 activated the SERCA2-tk reporter in a dose-dependent manner, doses of T3 as high as 500 nmol/L could not overcome the negative effects of FOG-2 (Figure 6c). These results confirm that FOG-2 disrupts T3-mediated TR1 transactivation of the SERCA2 promoter.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Our work demonstrates a novel role for FOG-2 in both adult heart disease and tissue-restricted T3 resistance. Increased FOG-2 expression in end-stage human heart failure, and at a time when CREB-S133A mice are susceptible to dying from heart failure,25 and wild-type mice subjected to transverse aortic constriction have decreased systolic function, attests to the fact that FOG-2 upregulation is a novel heart-failure associated feature. We demonstrate that FOG-2 disrupts T3-mediated transcription of the SERCA2 gene, which in cultured cardiomyocytes, cannot be overcome by high doses of T3. By lowering SERCA2 expression, increased FOG-2 expression may therefore contribute to the impaired systolic and diastolic function characteristic of end-stage heart failure. These observations have clinical implications because thyroid hormone therapy, long considered for treating heart disease, has been limited by its cardiotoxic and peripheral side effects.38
Downregulation of SERCA2 is a critical event that accompanies the transition to decompensated heart failure.39–41 We observed a novel physical interaction between FOG-2 and TR1, the principal TR-regulating SERCA2 in the myocardium. Furthermore, this interaction occurred in the absence and presence of T3, thus distinguishing FOG-2 from other corepressors whose binding affinities to nuclear hormone receptors are reduced by ligand.42 Because the FOG-2-R3A inactive mutant did not abrogate T3-mediated TR-dependent transactivation but permitted intact TR-dependent silencing of a TRE-driven reporter, these results implicate that FOG-2 abrogation occurs via its highly conserved N-terminus repression motif, which has been shown to exert its effects via interactions with a nucleosome-associated complex.36,43 Alternatively, FOG-2 may impair T3-dependent transcriptional activity through competition with TR1 for limiting amounts of p300,44 a coactivator required for T3-dependent transcriptional activity.45
Repression of endogenous SERCA2 in the absence of T3 suggests that FOG-2 also represses SERCA2 through mechanisms unrelated to T3 signaling. Sequences further upstream of the proximal SERCA2 promoter studied in this report that positively regulate the SERCA2 promoter46,47 are enriched with GATA4 consensus binding sites48 and have severely reduced transcriptional activity in severe LV pressure overload.47,48 Multiprotein complexes between FOG-2, GATA4, and other nuclear hormone receptors can cooperatively repress transcription21,22 and may also play a role in SERCA2 repression. Experiments are currently underway to address this question.
Consistent with our in vitro observations, in vivo cardiac overexpression of FOG-2 resulted in decreased expression of SERCA2 mRNA and protein. Furthermore, FOG-2 mouse hearts spontaneously developed multiple features of cardiomyopathy and a reversion to a fetal pattern of gene expression without gross or histological evidence of hypertrophy, a commonly accepted precursor to load-induced heart failure.49 The development of hypertrophy-independent cardiomyopathy in FOG-2 mice is reminiscent of several previously described mouse models of nonhypertrophic cardiomyopathy, including the Tg mutant CREB mouse25 and human idiopathic restrictive cardiomyopathy.50 Our findings suggest that FOG-2 may be a key downstream effector of signaling pathways responsible for mediating the transcriptional changes observed with heart failure via mechanisms independent of those which lead to pathological hypertrophy.
Recent studies supporting the necessary role of GATA4 for normal cardiac function and protection against load-induced heart failure51,52 may also shed light on the role of FOG-2 in cardiomyopathy. FOG-2 is a powerful repressor of GATA4-mediated gene expression19 and of cardiac myocyte hypertrophy in vitro.44 Similar to FOG-2 mice, heterozygous mutant GATA4 mice have systolic and diastolic dysfunction and blunted dP/dtmax and dP/dtmin responses to β-adrenergic stimulation. However, in contrast to FOG-2 mice, they do not develop progressive dysfunction and death, despite a nearly 50% reduction of GATA4 protein.51 FOG-2 mice also have more severe cardiac dysfunction and higher mortality than GATA4-deficient mice.52 These results suggest that the effects of FOG-2 overexpression cannot be explained simply by a loss of GATA4 activity and implicate GATA4-independent functions of FOG-2. We speculate that although GATA4 is necessary for compensatory hypertrophy in response to pathological stress,51 increased FOG-2 expression may directly trigger the transition to decompensated heart failure observed in end-stage cardiomyopathy.
Our study indicates that increased cardiac expression of FOG-2 promotes resistance of SERCA2 to T3 stimulation and may render the heart more susceptible to decompensation. This effect may extend broadly to other T3-regulated genes and pathways critical to efficient excitation–contraction coupling. Although it remains to be determined whether additional cardiac pathologies are associated with increased FOG-2 expression, our model suggests that therapies designed to decrease FOG-2 activity in the failing heart might slow the progression of heart failure. Defining the signaling pathways that regulate FOG-2 activity and the downstream targets of FOG-2 in cardiac myocytes will provide insight into mechanisms of heart failure progression.
|
Acknowledgments |
|---|
We thank Dr Jeffrey Leiden for support of these studies, Hua Lin for cardiac catheterization studies, and Dorothy Zhang for histology staining.
Sources of Funding
This work was supported by NIH grant R01-AA014140 (to G.S.H.) and T32-HL069770-01A1 (to R.R.) and American Heart Association Grant 0555877T (to G.S.H.).
Disclosures
None.
|
Footnotes |
|---|
Original received July 2, 2007; first resubmission received January 3, 2008; second resubmission received June 16, 2008; accepted July 10, 2008.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997; 100: 2315–2324.[Medline] [Order article via Infotrieve]
2. Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C, Allen PD, Komajda M, Schwartz K. Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990; 85: 305–309.[Medline] [Order article via Infotrieve]
3. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001; 344: 501–509.
4. van Tuyl M, Blommaart PE, de Boer PA, Wert SE, Ruijter JM, Islam S, Schnitzer J, Ellison AR, Tibboel D, Moorman AF, Lamers WH. Prenatal exposure to thyroid hormone is necessary for normal postnatal development of murine heart and lungs. Dev Biol. 2004; 272: 104–117.[CrossRef][Medline] [Order article via Infotrieve]
5. Arai M, Otsu K, MacLennan DH, Alpert NR, Periasamy M. Effect of thyroid hormone on the expression of mRNA encoding sarcoplasmic reticulum proteins. Circ Res. 1991; 69: 266–276.
6. Rohrer D, Dillmann WH. Thyroid hormone markedly increases the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in the rat heart. J Biol Chem. 1988; 263: 6941–6944.
7. Hamilton MA, Stevenson LW, Luu M, Walden JA. Altered thyroid hormone metabolism in advanced heart failure. J Am Coll Cardiol. 1990; 16: 91–95.[Abstract]
8. Wassen FW, Schiel AE, Kuiper GG, Kaptein E, Bakker O, Visser TJ, Simonides WS. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology. 2002; 143: 2812–2815.
9. Kinugawa K, Minobe WA, Wood WM, Ridgway EC, Baxter JD, Ribeiro RC, Tawadrous MF, Lowes BA, Long CS, Bristow MR. Signaling pathways responsible for fetal gene induction in the failing human heart: evidence for altered thyroid hormone receptor gene expression. Circulation. 2001; 103: 1089–1094.
10. Zhang J, Lazar MA. The mechanism of action of thyroid hormones. Annu Rev Physiol. 2000; 62: 439–466.[CrossRef][Medline] [Order article via Infotrieve]
11. Stoykov I, Zandieh-Doulabi B, Moorman AF, Christoffels V, Wiersinga WM, Bakker O. Expression pattern and ontogenesis of thyroid hormone receptor isoforms in the mouse heart. J Endocrinol. 2006; 189: 231–245.
12. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005; 26: 704–728.
13. Jeyakumar M, Tanen MR, Bagchi MK. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor. Mol Endocrinol. 1997; 11: 755–767.
14. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J. 1999; 18: 1900–1904.[CrossRef][Medline] [Order article via Infotrieve]
15. Yoh SM, Chatterjee VK, Privalsky ML. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors. Mol Endocrinol. 1997; 11: 470–480.
16. Safer JD, Cohen RN, Hollenberg AN, Wondisford FE. Defective release of corepressor by hinge mutants of the thyroid hormone receptor found in patients with resistance to thyroid hormone. J Biol Chem. 1998; 273: 30175–30182.
17. Svensson EC, Huggins GS, Lin H, Clendenin C, Jiang F, Tufts R, Dardik FB, Leiden JM. A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2. Nat Genet. 2000; 25: 353–356.[CrossRef][Medline] [Order article via Infotrieve]
18. Tevosian SG, Deconinck AE, Tanaka M, Schinke M, Litovsky SH, Izumo S, Fujiwara Y, Orkin SH. FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell. 2000; 101: 729–739.[CrossRef][Medline] [Order article via Infotrieve]
19. Svensson EC, Tufts RL, Polk CE, Leiden JM. Molecular cloning of FOG-2: a modulator of transcription factor GATA-4 in cardiomyocytes. Proc Natl Acad Sci U S A. 1999; 96: 956–961.
20. Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G, Orkin SH. FOG-2: a novel GATA-family cofactor related to multitype zinc-finger proteins Friend of GATA-1 and U-shaped. Proc Natl Acad Sci U S A. 1999; 96: 950–955.
21. Huggins GS, Bacani CJ, Boltax J, Aikawa R, Leiden JM. Friend of GATA 2 physically interacts with chicken ovalbumin upstream promoter-TF2 (COUP-TF2) and COUP-TF3 and represses COUP-TF2-dependent activation of the atrial natriuretic factor promoter. J Biol Chem. 2001; 276: 28029–28036.
22. Clabby ML, Robison TA, Quigley HF, Wilson DB, Kelly DP. Retinoid X receptor alpha represses GATA-4-mediated transcription via a retinoid-dependent interaction with the cardiac-enriched repressor FOG-2. J Biol Chem. 2003; 278: 5760–5767.
23. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR, Hintze TH, Lopaschuk GD, Recchia FA. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation. 2002; 106: 606–612.
24. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem. 2001; 276: 30245–30253.
25. Fentzke RC, Korcarz CE, Lang RM, Lin H, Leiden JM. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest. 1998; 101: 2415–2426.[Medline] [Order article via Infotrieve]
26. Subramaniam A, Jones WK, Gulick J, Wert S, Neumann J, Robbins J. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J Biol Chem. 1991; 266: 24613–24620.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95: 2509–2514.
28. Patten RD, Pourati I, Aronovitz MJ, Baur J, Celestin F, Chen X, Michael A, Haq S, Nuedling S, Grohe C, Force T, Mendelsohn ME, Karas RH. 17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res. 2004; 95: 692–699.
29. Gloss B, Giannocco G, Swanson EA, Moriscot AS, Chiellini G, Scanlan T, Baxter JD, Dillmann WH. Different configurations of specific thyroid hormone response elements mediate opposite effects of thyroid hormone and GC-1 on gene expression. Endocrinology. 2005; 146: 4926–4933.[CrossRef][Medline] [Order article via Infotrieve]
30. Gadbut AP, Toupin DK, Kilbourne EJ, Galper JB. Low density lipoproteins induce parasympathetic responsiveness in embryonic chick ventricular myocytes in parallel with a coordinate increase in expression of genes coding for the M2 muscarinic receptor, G alpha i2, and the acetylcholine-sensitive K+ channel. J Biol Chem. 1994; 269: 30707–30712.
31. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001; 98: 5116–5121.
32. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E, Conte JV, Tomaselli G, Garcia JG, Hare JM. Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. Physiol Genomics. 2005; 21: 299–307.
33. Subramaniam A, Gulick J, Robbins J. Analysis of the upstream regulatory region of a chicken skeletal myosin heavy chain gene. J Biol Chem. 1990; 265: 13986–13994.
34. Chen WJ, Lin KH, Lee YS. Molecular characterization of myocardial fibrosis during hypothyroidism: evidence for negative regulation of the pro-alpha1(I) collagen gene expression by thyroid hormone receptor. Mol Cell Endocrinol. 2000; 162: 45–55.[CrossRef][Medline] [Order article via Infotrieve]
35. Izumo S, Mahdavi V. Thyroid hormone receptor alpha isoforms generated by alternative splicing differentially activate myosin HC gene transcription. Nature. 1988; 334: 539–542.[CrossRef][Medline] [Order article via Infotrieve]
36. Lin AC, Roche AE, Wilk J, Svensson EC. The N termini of Friend of GATA (FOG) proteins define a novel transcriptional repression motif and a superfamily of transcriptional repressors. J Biol Chem. 2004; 279: 55017–55023.
37. Hartong R, Wang N, Kurokawa R, Lazar MA, Glass CK, Apriletti JW, Dillmann WH. Delineation of three different thyroid hormone-response elements in promoter of rat sarcoplasmic reticulum Ca2+ATPase gene. Demonstration that retinoid X receptor binds 5' to thyroid hormone receptor in response element 1. J Biol Chem. 1994; 269: 13021–13029.
38. Degens H, Gilde AJ, Lindhout M, Willemsen PH, Van Der Vusse GJ, Van Bilsen M. Functional and metabolic adaptation of the heart to prolonged thyroid hormone treatment. Am J Physiol Heart Circ Physiol. 2003; 284: H108–H115.
39. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 1993; 73: 184–192.[Abstract]
40. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G. Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation. 1995; 92: 778–784.
41. Miyamoto MI, del Monte F, Schmidt U, DiSalvo TS, Kang ZB, Matsui T, Guerrero JL, Gwathmey JK, Rosenzweig A, Hajjar RJ. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A. 2000; 97: 793–798.
42. Hu X, Lazar MA. Transcriptional repression by nuclear hormone receptors. Trends Endocrinol Metab. 2000; 11: 6–10.[CrossRef][Medline] [Order article via Infotrieve]
43. Roche AE, Bassett BJ, Samant SA, Hong W, Blobel GA, Svensson EC. The zinc finger and C-terminal domains of MTA proteins are required for FOG-2-mediated transcriptional repression via the NuRD complex. J Mol Cell Cardiol. 2008; 44: 352–360.[CrossRef][Medline] [Order article via Infotrieve]
44. Hirai M, Ono K, Morimoto T, Kawamura T, Wada H, Kita T, Hasegawa K. FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. J Biol Chem. 2004; 279: 37640–37650.
45. Li Q, Imhof A, Collingwood TN, Urnov FD, Wolffe AP. p300 stimulates transcription instigated by ligand-bound thyroid hormone receptor at a step subsequent to chromatin disruption. EMBO J. 1999; 18: 5634–5652.[CrossRef][Medline] [Order article via Infotrieve]
46. Takizawa T, Arai M, Yoguchi A, Tomaru K, Kurabayashi M, Nagai R. Transcription of the SERCA2 gene is decreased in pressure-overloaded hearts: a study using in vivo direct gene transfer into living myocardium. J Mol Cell Cardiol. 1999; 31: 2167–2174.[CrossRef][Medline] [Order article via Infotrieve]
47. Aoyagi T, Yonekura K, Eto Y, Matsumoto A, Yokoyama I, Sugiura S, Momomura S, Hirata Y, Baker DL, Periasamy M. The sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene promoter activity is decreased in response to severe left ventricular pressure-overload hypertrophy in rat hearts. J Mol Cell Cardiol. 1999; 31: 919–926.[CrossRef][Medline] [Order article via Infotrieve]
48. Eizema K, Van Heugten HA, Bezstarosti K, Van Setten MC, Lamers JM. In vitro analysis of SERCA2 gene regulation in hypertrophic cardiomyocytes and increasing transfection efficiency by gene-gun biolistics. Ann N Y Acad Sci. 1999; 874: 111–124.[CrossRef][Medline] [Order article via Infotrieve]
49. Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999; 341: 1276–1283.
50. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000; 101: 2490–2496.
51. Bisping E, Ikeda S, Kong SW, Tarnavski O, Bodyak N, McMullen JR, Rajagopal S, Son JK, Ma Q, Springer Z, Kang PM, Izumo S, Pu WT. Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure. Proc Natl Acad Sci U S A. 2006; 103: 14471–14476.
52. Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res. 2006; 98: 837–845.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||